Vis enkel innførsel

dc.contributor.authorStrell, Carina
dc.contributor.authorStenmark Tullberg, Axel
dc.contributor.authorEdelmann, Reidunn Jetne
dc.contributor.authorAkslen, Lars Andreas
dc.contributor.authorMalmström, Per-Uno
dc.contributor.authorFernö, Mårten
dc.contributor.authorHolmberg, Erik
dc.contributor.authorÖstman, Arne
dc.contributor.authorKarlsson, Per
dc.date.accessioned2021-08-18T07:44:05Z
dc.date.available2021-08-18T07:44:05Z
dc.date.created2021-08-06T15:40:47Z
dc.date.issued2021
dc.identifier.issn0167-6806
dc.identifier.urihttps://hdl.handle.net/11250/2769983
dc.description.abstractPurpose Predictive biomarkers are needed to aid the individualization of radiotherapy (RT) in breast cancer. Cancer-associated fibroblasts have been implicated in tumor radioresistance and can be identified by platelet-derived growth factor receptor-beta (PDGFRb). This study aims to analyze how PDGFRb expression affects RT benefit in a large randomized RT trial. Methods PDGFRb was assessed by immunohistochemistry on tissue microarrays from 989 tumors of the SweBCG91RT trial, which enrolled lymph node-negative, stage I/IIA breast cancer patients randomized to RT after breast-conserving surgery. Outcomes were analyzed at 10 years for ipsilateral breast tumor recurrence (IBTR) and any recurrence and 15 years for breast cancer specific death (BCSD). Results PDGFRb expression correlated with estrogen receptor negativity and younger age. An increased risk for any recurrence was noted in univariable analysis for the medium (HR 1.58, CI 95% 1.11–2.23, p = 0.011) or PDGFRb high group (1.49, 1.06–2.10, p = 0.021) compared to the low group. No differences in IBTR or BCSD risk were detected. RT benefit regarding IBTR risk was significant in the PDGFRb low (0.29, 0.12–0.67, p = 0.004) and medium (0.31, 0.16–0.59, p < 0.001) groups but not the PDGFRb high group (0.64, 0.36–1.11, p = 0.110) in multivariable analysis. Likewise, risk reduction for any recurrence was less pronounced in the PDGFRb high group. No significant interaction between RT and PDGFRb-score could be detected. Conclusion A higher PDGFRb-score conferred an increased risk of any recurrence, which partly can be explained by its association with estrogen receptor negativity and young age. Reduced RT benefit was noted among patients with high PDGFRb, however without significant interaction.en_US
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titlePrognostic and predictive impact of stroma cells defned by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trialen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s) 2021en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1007/s10549-021-06136-4
dc.identifier.cristin1924454
dc.source.journalBreast Cancer Research and Treatmenten_US
dc.source.pagenumber45-55en_US
dc.identifier.citationBreast Cancer Research and Treatment. 2021, 187, 45-55.en_US
dc.source.volume187en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal